News | December 10, 2025
Novo Nordisk completes acquisition of Akero Therapeutics
Akero became a wholly owned subsidiary of Novo Nordisk
Akero became a wholly owned subsidiary of Novo Nordisk
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
HYMPAVZI’s safety profile was generally favorable
The launch of the study was on the occasion of the International Day of Persons with Disabilities
76 of 180 long COVID-associated genes also linked to ME
Subscribe To Our Newsletter & Stay Updated
